|
Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: A phase I trial. |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Reflexion Medical |
Patents, Royalties, Other Intellectual Property - I have a patent on the utilization of a monoclonal antibody and we license this for use. We receive royalties <$1000 per year on this license. |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - Wolters Kluwer |
|
|
Employment - MD Anderson Cancer Center; MD Anderson Cancer Center |
Leadership - MolecularMatch; MolecularMatch |
Stock and Other Ownership Interests - Alpine Immune Sciences; Checkmate Pharmaceuticals; Mavupharma; MolecularMatch; Nanobiotix; Nanorobotix; Oncorena; Reflexion Medical; Reflexion Medical |
Honoraria - Aileron Therapeutics; American Association of Physicists in Medicine; Nanobiotix; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology |
Consulting or Advisory Role - Alpine Immune Sciences; AstraZeneca; Checkmate Pharmaceuticals; Legion Healthcare Partners; Mavu Pharmaceutical; MolecularMatch; Oncorena; Reflexion Medical |
Research Funding - Aileron Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Mavu Pharmaceutical; Merck; Nanobiotix |
Patents, Royalties, Other Intellectual Property - MolecularMatch |
Travel, Accommodations, Expenses - AACR; Aileron Therapeutics; American Society for Radiation Oncology; Gustave Roussy Cancer Center; IASLC; MedAustron; Nanobiotix; Radiation Research Society; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; Turkish Society of Lung Cancer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Angiochem (Inst); Bayer; Blueprint Medicines; Genentech/Roche (Inst); Juno Therapeutics (Inst); Novocure (Inst); Vanquish Oncology |
|
|
|
Research Funding - Elekta |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; EMD Serono; Lilly |
|
|
|
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer |
Consulting or Advisory Role - MedImmune |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ayala Pharmaceuticals; Cellestia Biotech; E.R. Squibb Sons, LLC; Sanofi/Regeneron |
Research Funding - AstraZeneca/MedImmune (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst) |
|
|
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda |
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Shattuck Labs |
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst) |